We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Psoriasis and Wound Healing Gene Identified

By LabMedica International staff writers
Posted on 03 Jul 2012
A gene has been identified that regulates keratinocyte proliferation and differentiation after skin injury and, when overexpressed, can induce the autoimmune skin disorder psoriasis.

Investigators at the University of California, San Diego (USA) analyzed skin biopsies of patients with and without psoriasis, as well as the skin of mice with psoriasis and with wounds on their backs.

They reported in the June 21, 2012, online edition of the journal Immunity that regenerating islet-derived protein 3-alpha (REG3A) was highly expressed in keratinocytes during psoriasis and wound repair and in induced psoriatic skin lesions in mice. More...
This gene encodes a pancreatic secretory protein that may be involved in cell proliferation or differentiation. The enhanced expression of this gene has been observed during pancreatic inflammation and liver carcinogenesis.

In experiments carried out on mice wound and psoriasis models, the investigators found that inhibition of REG3A slowed wound-healing but reversed psoriasis.

The expression of REG3A by keratinocytes was shown to be induced by interleukin-17 (IL-17) via activation of the keratinocyte-encoded IL-17 receptor A (IL-17RA). This activity acted to inhibit terminal differentiation and increased cell proliferation by binding to exostosin-like 3 (EXTL3) protein followed by activation of phosphatidylinositol 3 kinase (PI3K) and the kinase Akt (protein kinase B).

Senior author Dr. Richard L. Gallo, professor of medicine at the University of California, San Diego, said, “The discovery of REG3A’s dual roles provides a new target for different therapies. A drug that inhibits the expression of REG3A could represent a more targeted way to treat psoriasis without the systemic immunosuppression problems of current treatments. Conversely, a drug that stimulates or mimics REG3A could boost cell growth and improve wound healing.”

Related Links:

University of California, San Diego



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Chromogenic Culture System
InTray™ COLOREX™ ECC
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.